NeuroMetrix, Inc. - NURO STOCK NEWS

NeuroMetrix, Inc. (Nasdaq: NURO) has appointed Brandi Damkier as Vice President of Clinical Partnerships. In her role, Damkier will focus on expanding the DPNCheck^® clinical partnerships and enhancing the company’s presence in value-based healthcare. With over 20 years of experience in health plans and healthcare technology, her previous roles include leadership positions at eHealth, CareCentrix, and NTT Data. CEO Shai N. Gozani expressed confidence in Damkier's capabilities at this crucial time for developing DPNCheck within Medicare Advantage.

NeuroMetrix, Inc. (Nasdaq: NURO) announced that Dr. Shai N. Gozani, President and CEO, will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 AM (ET) for 90 days. Dr. Gozani will discuss the company's product offerings, growth initiatives, and outlook for 2022. NeuroMetrix specializes in non-invasive medical devices for diagnosing and treating pain and neurological disorders, with products like DPNCheck®, ADVANCE®, and Quell®.

NeuroMetrix, Inc. (NURO) reported Q3 2021 revenue of $2.1 million, a slight increase from Q3 2020. However, gross margin decreased to 70.0% from 73.6% due to rising component costs. Operating expenses grew by $0.4 million mainly from regulatory activities. The net loss widened to $0.7 million from $0.3 million the previous year. The DPNCheck® product remained a key revenue driver, and new SVP Susan Bell will enhance the Medicare Advantage strategy. The company raised $15.8 million via stock sales, ending Q3 with $23.2 million cash on hand.

NeuroMetrix, Inc. (Nasdaq: NURO) has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care. Ms. Bell aims to enhance the company's DPNCheck® business, focusing on the Medicare Advantage market. DPNCheck is vital for screening diabetic peripheral neuropathy, a common diabetes complication. With over 20 years in sales and strategy, her experience is expected to drive growth. NeuroMetrix plans to launch its second-generation DPNCheck device, indicating a potential expansion in its value-based healthcare footprint.

NeuroMetrix (NURO) is set to release its 2021 third quarter financial results before the market opens on October 21, 2021. A conference call will follow at 8:00 a.m. ET on the same day to discuss the results and relevant business developments. Investors can access the call domestically at 844-787-0799 or internationally at 661-378-9630, using the confirmation code 7683407. Financial details will also be available on the company's website under 'Investor Relations.'

NeuroMetrix focuses on non-invasive medical devices for treating pain and neurological disorders, with products like DPNCheck®, ADVANCE®, and Quell®.

NeuroMetrix, Inc. (Nasdaq: NURO) has submitted a De Novo request to the FDA for Quell as a prescription treatment for fibromyalgia symptoms in adults, following its Breakthrough Designation received in July. Fibromyalgia, affecting 5 to 15 million Americans, lacks FDA-approved medical devices for treatment. The De Novo request includes results from a trial involving 119 subjects, showing 57% improvement in quality-of-life for those using Quell compared to 34% in the sham group (p=0.014). A commercial launch is anticipated in the second half of 2022, pending FDA approval.

NeuroMetrix (NASDAQ: NURO) has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner. C2SHIP, a National Science Foundation-funded consortium, aims to develop technologies for personalized at-home healthcare. NeuroMetrix will apply its Quell® wearable neuromodulation technology and the Quell Health Cloud chronic pain database for novel therapeutic applications. This partnership seeks to enhance chronic pain management and improve patient outcomes through advanced data science and collaboration with leading academic institutions.

NeuroMetrix, Inc. (Nasdaq: NURO) recently announced a publication on the effects of wearable transcutaneous electrical nerve stimulation for fibromyalgia in the Journal of Pain Research. This study involved 119 subjects over a 3-month period, comparing active and sham treatments using the Quell device. Importantly, the Quell device's use for fibromyalgia remains investigational and has not received FDA approval. Fibromyalgia affects 2-6% of the U.S. population, highlighting the need for effective non-pharmacological treatments. NeuroMetrix focuses on non-invasive medical devices for pain and neurological disorders.

NeuroMetrix, Inc. (NASDAQ: NURO) reported Q2 2021 revenue of $2.2 million, a 63% increase from Q2 2020's $1.4 million, driven mainly by the domestic Medicare Advantage business. The gross margin improved to 74.8%, up from 63.6% year-over-year. The net loss narrowed to $0.5 million from $0.8 million. Key developments included the receipt of Breakthrough Device Designation from the FDA for the Quell device aimed at fibromyalgia treatment and the potential for a regulatory filing later this year.